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NOISY UPPER RESPIRATORY TRACT SECRETIONS: PHARMACOLOGICAL 
MANAGEMENT  
 
Upper respiratory tract secretion accumulation with noisy breathing (‘death rattle’) is 
caused by salivary secretions pooling within the hypopharynx. It occurs in people who 
cannot swallow, usually in the last days of life.1-3 It is reported in 12–92% of dying 
patients3-6; the weighted mean prevalence is 35%.5 The noise and secretions can be 
distressing for some family members and staff.5-8 They are reportedly not associated 
with subjective respiratory distress,4, 5 although those with the problem often have 
impaired consciousness so patient impact is unclear.5 Antimuscarinic drugs (e.g. 
glycopyrronium and hyoscine butylbromide) reduce new secretion formation.2-4 
 
Systematic reviews have found no benefit of antimuscarinics over placebo. They 
advise against their routine use once noisy upper respiratory tract secretions are 
present.3, 5, 9 Although they reduce production, they do not remove existing 
secretions. The idea of preventative prophylactic administration, before secretions 
occur, for those at risk is tantalising. It is not currently possible to identify those at 
higher risk of respiratory secretions.9, 10 
 
An open-label exploratory study in dying hospice patients with impaired 
consciousness compared prophylactic hyoscine butylbromide (n=51) with 
administration after secretions developed (n=81).11 The loudness of the secretions’ 
noise was determined by the nurse in charge. Prophylactic hyoscine butylbromide 
was more effective; 6% had noisy secretions in the prophylactic arm versus 61% in 
the standard treatment arm. Dose titration did not occur (all received hyoscine 
butylbromide as a 20mg stat dose followed by 60mg/day).11 Onset of death rattle 
was also delayed in the prophylactic group (12 hours v 36 hours).11 This was an 
important exploratory study although it was unblinded and side effects were not 
reported.11  
 
Before implementation into routine clinical practice, data on the benefits and harms 
of prophylactic antimuscarinics are needed from powered placebo-controlled 
studies.12, 13 These are ongoing.14 Without a blinded placebo comparator arm, bias 
(e.g. information/observer) is likely to influence the results. A previous uncontrolled, 
unblinded study of antimuscarinics reported benefit,15 but this effect no longer 
remained in controlled blinded studies.3, 5, 9, 16 This might partly be due to reduction in 
noisy breathing with placebo.16 Furthermore, we do not fully understand the natural 
history of noisy secretions (hence the need for a placebo arm) and antimuscarinic 
side effects (e.g. constipation, dry mouth, and urinary retention which can also cause 
distress).2, 13, 17 Prophylactic hyoscine butylbromide in all dying patients cannot be 
recommended.12, 13 It remains important to assess, effectively communicate with the 
patient’s family (even pre-emptively), and use non-pharmacological measures.1, 3, 6, 
12, 18, 19 If pharmacotherapy is indicated, frequent assessment for efficacy and 
adverse effects is needed, stopping after 12-24 hours if ineffective (although dose 
titration might be needed).3, 19 In future studies, an important clinical outcome might 
be the views, concerns, and distress of family/carers about noisy upper respiratory 
tract secretions. 
 
 
 
Box - Practical management of noisy upper respiratory tract secretions 
 
Consider pre-emptive discussion and preparing relatives and carers about end of 
life care and related potential symptoms. 
 
Assessment  
 
• Are they upper respiratory tract? Or just another cause of the noisy 
breathing (e.g. chest infection, pulmonary oedema) 
• Is anything reversible? 
• Do they appear distressing to the patient? 
• Are they distressing to relatives/carers? 
Management 
 
• Discuss and explain noisy respiratory secretions to relatives/carers (and if 
appropriate the patient) - this can help alleviate distress 
• Use non-pharmacological measures, e.g. repositioning  
• If distressing, a trial of antimuscarinics could be considered. This should be 
discussed with relatives, the patient monitored for adverse effects and 
discontinued after 24 hours if ineffective (dose titration might be needed). If 
drugs are used, they should be used promptly as they do not remove 
formed secretions. Refer to local guidelines, either hyoscine butylbromide or 
glycopyrronium are most common, both given subcutaneously: 
o Hyoscine butylbromide: 20mg stat with 60mg/day. As required doses 
can continue to be given a maximum of hourly. Maximum usual daily 
dose is 120mg. 
o Glycopyrronium: 200mcg stat with 800mcg/day. As required doses 
can be given a maximum of hourly. Maximum usual daily dose is 
1200mcg. 
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